OncoSec Medical (ONCS)
OncoSec Medical Statistics
Share Statistics
OncoSec Medical has 5.96M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 5.96M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.34M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.86 and the forward PE ratio is null. OncoSec Medical's PEG ratio is 0.02.
| PE Ratio | -0.86 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 4.78 |
| P/FCF Ratio | -0.9 |
| PEG Ratio | 0.02 |
Enterprise Valuation
OncoSec Medical has an Enterprise Value (EV) of 23.13M.
| EV / Sales | 0 |
| EV / EBITDA | -0.64 |
| EV / EBIT | -0.72 |
| EV / FCF | -0.71 |
Financial Position
The company has a current ratio of 2.3, with a Debt / Equity ratio of 1.01.
| Current Ratio | 2.3 |
| Quick Ratio | 2.3 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.19 |
| Interest Coverage | -1768.8 |
Financial Efficiency
Return on Equity is -558.64% and Return on Invested Capital is -274.32%.
| Return on Equity | -558.64% |
| Return on Assets | -156.23% |
| Return on Invested Capital | -274.32% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-854.49K |
| Employee Count | 40 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.33M |
| Effective Tax Rate | 8.89% |
Stock Price Statistics
The stock price has increased by 1.01% in the last 52 weeks. The beta is 2, so OncoSec Medical's price volatility has been higher than the market average.
| Beta | 2 |
| 52-Week Price Change | 1.01% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 3.69 |
| Relative Strength Index (RSI) | 31.67 |
| Average Volume (20 Days) | 2.13M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -37.01M |
| Net Income | -34.18M |
| EBITDA | -35.92M |
| EBIT | -37.49M |
| Earnings Per Share (EPS) | -19.13 |
Balance Sheet
The company has 12.3M in cash and 6.17M in debt, giving a net cash position of 6.12M.
| Cash & Cash Equivalents | 12.3M |
| Total Debt | 6.17M |
| Net Cash | 6.12M |
| Retained Earnings | -285.96M |
| Total Assets | 8.87M |
| Working Capital | -789.47K |
Cash Flow
In the last 12 months, operating cash flow was -32.14M and capital expenditures -244.86K, giving a free cash flow of -32.38M.
| Operating Cash Flow | -32.14M |
| Capital Expenditures | -244.86K |
| Free Cash Flow | -32.38M |
| FCF Per Share | -18.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ONCS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -116.82% |
| FCF Yield | -110.68% |
Analyst Forecast
Currently there are no analyst rating for ONCS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Nov 9, 2022. It was a backward split with a ratio of 1:22.
| Last Split Date | Nov 9, 2022 |
| Split Type | backward |
| Split Ratio | 1:22 |
Scores
| Altman Z-Score | -59.8 |
| Piotroski F-Score | 2 |